Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Satellos Bioscience Inc.
MSLE
$7.14 (- $0.19 - 2.59%)
Last updated: Previous Close (2026-05-21)
About the Company
Satellos Bioscience Inc. is a biotechnology company specializing in regenerative medicine for degenerative muscle diseases. It develops novel small-molecule therapeutics using its proprietary MyoReGenX™ platform, an automated microscopy system that analyzes muscle stem cell polarity and regeneration deficits ex vivo to identify therapeutic targets. The company's lead candidate, SAT-3247, is an oral drug in clinical development targeting Duchenne muscular dystrophy by restoring the body's innate muscle repair process disrupted by dystrophin absence, specifically through pathways like AAK1 to promote asymmetric stem cell division. Focused on unmet needs in rare diseases, Satellos Bioscience Inc. operates primarily in Canada with subsidiaries in Australia and the US, advancing a pipeline informed by stem cell biology expertise. Founded around 2018 and headquartered in Toronto, Ontario, the firm employs approximately 14-17 professionals under CEO Frank Gleeson, emphasizing innovation in muscle regeneration to address conditions where natural repair mechanisms fail.
Price History
Latest News for MSLE
Satellos Up Near 10% In US Premarket As Presents Interim SAT-3247 Clinical and Biomarker Data in DMD at Florida Conference
Satellos Bioscience (MSCL.TO, NASDAQ: MSLE) was at last look up near 10% in US premarket trade Tuesd
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP studyProteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administra
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
TORONTO, February 24, 2026--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
TORONTO, February 18, 2026--Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, Feb. 24, 2026, at 3:30 p.m. ET, featuring Kevin M. Flanigan, MD, the Wolfe Foundation Endowed Chair in Neuromuscular Research at Nationwide Children’s Hospital and professor of pediatrics a
Satellos to Participate in Upcoming Investor Conferences
TORONTO, February 17, 2026--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, today announced that management will present at and participate in the following investor conferences:
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
TORONTO, February 12, 2026--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy ("Duchenne" or "DMD").